Navigation Links
Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials

CHICAGO, June 4, 2011 /PRNewswire/ -- Data presented at the 47th American Society of Clinical Oncology (ASCO) annual meeting demonstrate the potential of circulating tumor cells (CTC) as a biomarker for metastatic prostate cancer clinical trials.  This study represents the first randomized, double-blind, placebo controlled Phase III trial to evaluate CTCs as a potential biomarker for overall survival.  Biomarkers are of scientific interest as, if validated, they could be used as a surrogate for a clinical endpoint and may help accelerate the clinical trial process.  

Results of the study titled, "Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration resistant prostate cancer (mCRPC)" indicated that pre-treatment, CTCs and lactate dehydrogenase (LDH), both alone and in combination, were prognostic biomarkers, while baseline prostate-specific antigen (PSA) was not.  Following the start of treatment, CTC counts were measured at four, eight and 12 weeks.  The data suggest that changes in CTC counts can predict overall survival during treatment.  Data also indicated LDH was strongly associated with survival.  

"Establishing CTCs as a biomarker or part of a biomarker panel that is a surrogate-endpoint for survival would be an important step toward our goal of enabling shorter trials and more rapid drug approvals in prostate cancer," said Howard Scher, M.D., the lead author of the study and chief of the genitourinary oncology service at the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan-Kettering Cancer Center. 

"As the only device with regulatory clearance to capture and count CTCs, we are excited that the data substantiates the prognostic value of CELLSEARCH®," said Robert McCormack, Ph.D. and Head of Technology Innovation at Veridex, LLC.  "We look forward to further investigating the potential predictive benefit of CTCs in metastatic prostate cancer clinical trials as there are limited ways of assessing therapeutic benefit in this disease, especially when it has metastasized to the bone."

Additional studies are underway to further validate CTCs as a surrogate endpoint in metastatic prostate cancer studies.

Study Design

The CTC analysis was conducted to determine if CTCs could be used as a surrogate for overall survival.  It was performed in 900 of the 1195 enrolled study patients with metastatic castration-resistant prostate cancer post-docetaxel being treated with either abiraterone acetate plus prednisone or placebo plus prednisone.  CTCs were counted (cells/7.5 mL) along with other biomarkers including PSA, LDH, hemoglobin, alkaline phosphatase at screening and baseline and post-baseline at four, eight and 12 weeks. Analyses were conducted for these biomarkers individually and collectively.

Veridex provided product support for the study. 

Dr. Howard Scher has provided consulting services to the company. 

Additional Data Presented at ASCO Substantiates In Vitro Diagnostic Use of CELLSEARCH® CTC Test

An independent study investigating the in vitro diagnostic use of CTC testing found that the number of CTCs in the blood may help physicians more reliably assess treatment benefit for patients with metastatic breast cancer.  The study, a large-scale retrospective analysis using blinded data to create a pooled dataset of 841 patients from cancer centers around the world, found that CTC count at or above the threshold of five was reliably associated with disease progression.  Further, the predictive value of CTCs was not affected by treatment type (chemotherapy, endocrine therapy, biologic therapy), tumor type (hormone receptor positive/negative, HER2 positive/negative), or sites of disease involvement.  The study was lead by Minetta Liu, M.D., Georgetown Lombardi Comprehensive Cancer Center and will be presented during a poster session on Monday, June 6th, 2011.

Dr. Minetta Liu has provided consulting services to the company. 

About Circulating Tumor Cells

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream.  The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.


CELLSEARCH® is the first and only regulatory-cleared in vitro diagnostic test to capture and count CTCs to determine the prognosis of patients with metastatic breast, colorectal or prostate cancer.  The test can be administered at any time during the course of therapy as a routine blood test.  It is used in combination with other tests and a clinician's assessment, to provide a more complete picture of a patient's prognosis.

About Veridex, LLC

Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians with high-value diagnostic oncology products.  Veridex's IVD products may significantly benefit patients by helping physicians make more informed decisions that enable better patient care.  Veridex's Clinical Research Solutions provide tools and services that may be used for the selection, identification and enumeration of targeted rare cells in peripheral blood for the identification of biomarkers, aiding scientists in their search for new, targeted therapies.  For more information, visit

About Abiraterone

In the U.S., abiraterone acetate is marketed as ZYTIGA™ by Centocor Ortho Biotech, Inc. an affiliate of Veridex.  It was developed by Ortho Biotech Oncology Research & Development, unit of Cougar Biotechnology, Inc. and was approved by the U.S. Food & Drug Administration on April 28, 2011.  Marketing authorization applications for ZYTIGA have been filed with other regulatory authorities around the world.  For more information about ZYTIGA, visit

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting
2. American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA
3. American Stroke Association Late-Breaking Science Report: Antiplatelet Drug May Be Better Than Aspirin in Preventing Recurrent Strokes
4. American Heart Association Late-Breaking Clinical Trial Report: New Reversible Oral Drug Reduces Cardiac Events in Primary PCI Patients
5. American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis
7. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
8. Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
9. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
10. Atritech to Participate in Late-Breaking Clinical Trial Presentation at American College of Cardiology Meeting
11. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 On Tuesday, ... federal bellwether trial against Wright Medical Technology, Inc. ... their Conserve metal-on-metal hip implant device, awarded $11 ... a two week trial and three days of ... hip device was defectively designed and unreasonably dangerous, ...
(Date:11/25/2015)...  ARKRAY USA , Inc., a ... demonstrating the accuracy of its blood glucose meter systems. ... Diabetes and Cardiovascular Disease in Los Angeles ... ® 01 meter and the Assure ® ... to accurately measure glucose levels in blood is essential ...
(Date:11/25/2015)... MELVILLE, N.Y. , Nov. 25, 2015  Henry ... products and services to office-based dental, medical and animal ... Dental (GNYDM) Meeting the Henry Schein ConnectDental® Pavilion ... industry,s broadest array of open solutions designed to help ... Click here for a schedule of ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software helps ... creates an agreement between the practice owner and the patient that automatically manages ... and projections. Click here to learn more. , According ...
(Date:11/24/2015)... ... 2015 , ... New patients who wish to seek treatment for missing teeth ... at her Mississauga, ON practice. Dr. Williams has been providing dental service for over ... , Missing teeth can lead to a variety of complications if they are not ...
(Date:11/24/2015)... ... November 24, 2015 , ... ThirdLove, the fast-growing ... a week early, offering 40% off select bras and underwear styles, now through ... both mobile fit technology and the latest fashion, quickly becoming the next generation ...
(Date:11/24/2015)... ... November 24, 2015 , ... DMG Productions announced that they will feature ... quarter 2016 via Discovery Channel. Dates and show times TBA. , Aphria, Inc., is ... the business of producing and supplying medical marijuana pursuant to the Marijuana for Medical ...
(Date:11/24/2015)... Lake City, UT (PRWEB) , ... November 24, 2015 , ... ... to Forbes Magazine. For a business, it is critical that the first impression be ... a business, they are not likely to buy anything or want to return. They ...
Breaking Medicine News(10 mins):